tcsc2899 Balsalazide

Balsalazide could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.

In Vivo: At the endpoint, the protein production of MIP-1β, MCP-1, IL-6, and IL-10 in the colon tissues decrease in concordance with the plasma concentrations of the cytokines. The drug-treated groups reveal lower expression of p-STAT3 compared to the CAC group. In addition, BCL2 decreases and BAX increases markedly in the BSZ+VSL#3 group^[1]. Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug^[2].